Identification and validation of HLA-A24 XBP1, CD138, and CS1 peptides and induction of antigensspecific CD8+ T cell immunity using a multipeptide cocktail: Preclinical basis for vaccine therapy in HLA-A24 patients with
XBP1 (X-box binding protein 1), CD138 (Syndecan-1) and CS1 (SLAMF7

